Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
19.34
-0.22 (-1.12%)
Apr 1, 2026, 11:53 AM EDT - Market open
Viridian Therapeutics Employees
Viridian Therapeutics had 252 employees as of December 31, 2025. The number of employees increased by 109 or 76.22% compared to the previous year.
Employees
252
Change (1Y)
109
Growth (1Y)
76.22%
Revenue / Employee
$281,147
Profits / Employee
-$1,118,762
Market Cap
1.98B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 252 | 109 | 76.22% | 252 | 0 |
| Dec 31, 2024 | 143 | 49 | 52.13% | 143 | 0 |
| Dec 31, 2023 | 94 | 8 | 9.30% | 94 | 0 |
| Dec 31, 2022 | 86 | 36 | 72.00% | 86 | 0 |
| Dec 31, 2021 | 50 | 23 | 85.19% | 50 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ultragenyx Pharmaceutical | 1,371 |
| Adaptive Biotechnologies | 624 |
| Galapagos NV | 558 |
| Agios Pharmaceuticals | 540 |
| Syndax Pharmaceuticals | 298 |
| Stoke Therapeutics | 170 |
| Aurinia Pharmaceuticals | 128 |
VRDN News
- 2 days ago - Why Is Viridian Therapeutics Stock Falling Monday? - Benzinga
- 2 days ago - Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease - Business Wire
- 4 weeks ago - Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 2 months ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Viridian Therapeutics Prepares for Transformational 2026 - Business Wire
- 3 months ago - Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire
- 3 months ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 5 months ago - Viridian Therapeutics Is Ready For An Eventful 2026 - Seeking Alpha